Salamanca

• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel … Ended recruitment
  2023-505219-19-00 9 2019-09-03 Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM
• A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other L … Ended recruitment
  2022-502498-40-00 5 2019-07-26 myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibr
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Participants with … Ended recruitment
  2023-508463-71-00 5 2018-11-30 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year … Ended recruitment
  2024-516905-22-00 5 2018-10-22 Multiple myeloma
• A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subject … Ended recruitment
  2023-506112-40-00 5 2018-09-26 R/R Multiple Myeloma
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi … Ended recruitment
  2024-510967-41-00 5 2018-09-21 Metastatic colorectal cancer
• Talquetamab (GPRC5D and CD3 antibody) in Relapsed or Refractory Multiple Myeloma Ended recruitment
  2023-504581-29-00 7 2018-04-26 Multiple myeloma
• Transplant BRaVE NHL: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse … Ended recruitment
  2023-510556-22-00 4 2018-03-05 non-Hodgkin lymphoma (NHL)
• Darolutamide vs ADT in hormone naïve Pca Ended recruitment
  2024-510840-30-00 4 2017-12-01 Hormone Naive Prostate Cancer
• An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma Ended recruitment
  2023-503438-40-00 7 2017-10-05 Relapsed/Refractory Multiple Myeloma
• A research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-ris … Ended recruitment
  2024-513450-30-00 5 2017-09-25 very high risk localized or locally advanced prostate cancer
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment
  2023-510298-33-00 4 2016-11-29 Prostate Cancer
• Study to Evaluate Imetelstat (GRN163L) in Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Ended recruitment
  2024-511348-25-00 10 2015-12-11 Myelodysplastic syndromes (MDS)
• A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly sympto … Ended recruitment
  2023-510453-41-00 5 2015-10-26 Castration resistant prostate cancer patients metastatic to bone.
• An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in … Ended recruitment
  2024-513521-23-00 5 2015-08-19 Prostate Cancer
• Study to evaluate the effectiveness of a combination of 3 treatments, followed by transplantation of their own blood cell progenitor cells f … Ended recruitment
  2024-516908-42-00 4 2015-06-15 Smoldering multiple myeloma with high risk of progression to symptomat
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Ended recruitment
  2024-517622-25-00 5 2013-12-06 Patients with localized prostate cancer and high-risk features of rela
• A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Ended recruitment
  2023-503803-27-00 5 2013-10-25 B-cell non-Hodgkin's lymphoma and cGVHD
• A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms Halted
  2025-520786-44-00 7 2025-10-21 Myelodysplastic syndromes
• Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma Halted
  2023-510560-12-00 4 2024-10-03 High-risk smoldering multiple myeloma

Showing 337–360 of 470 trials